that could be used in combat or by terrorists. The Department of Defense for using its technology to counter nerve agents notably, the Company has been awarded a grant from the U.S. Department of Defense for counteracting chemical warfare agents and will be used by muscle. This capability is the basis of a multi-year grant from the U.S. Department of Defense for using its technology to counter nerve agents that could be used in combat or by terrorists.

Near-term Target Markets: Cancer therapy and cancer imaging

Key Value Drivers

Technology: SGT's core technology involves a nanocomplex that "homes" to cancer cells like a targeted missile with minimal "collateral damage" to normal cells. Tumor-specific delivery after systemic (i.v.) administration of the nanocomplex is achieved via a targeting moiety that recognizes a feature common to a very wide variety of tumor types including the most common human malignancies.

Competitive Advantage: SGT's nanocomplex technology is based on a patent portfolio that includes 122 issued patents. Human clinical trials attest to the safety and efficacy of the delivery system. The SGT nanocomplex targets both cancer stem cells and bulk tumor cells and actively crosses the blood-brain barrier (BBB) to deliver therapeutic molecules and imaging agents (e.g., gadolinium-based contrast agents) to brain tumors. The versatility and performance characteristics of the SGT nanodelivery system are second to none. The product SGT-Gad crosses the intact BBB and can enable detection of smaller clusters of primary and metastatic tumor cells in the brain and elsewhere than currently used MRI contrast agents.

Plan & Strategy: The Company is conducting several clinical trials to develop its therapeutic products and seeks to license the imaging applications of its technology as well as other uses of its technology to one or more appropriate partners.

Management

Leadership: Joe B. Harford, PhD, President & CEO, conducted research and held senior administrative positions within the National Cancer Institute and previously served as Chief Scientific Officer in a privately held biotechnology company.

Chief Scientific & Clinical Advisors:

- **Professor Esther H. Chang**: The technology that undergirds SGT is based on the inventions of Dr. Chang of Georgetown University's Lombardi Comprehensive Cancer Center who serves as the Chief Scientific Advisor to SGT and is President of the American Society for Nanomedicine.

- **Daniel D. Von Hoff, M.D., F.A.C.P.**: Serving as SGT's Chief Clinical Advisor, Dr. Von Hoff is Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for HonorHealth's Clinical Research Institute and a Professor of Medicine at the University of Arizona.

Product Development

Cancer Therapy: SGT currently is conducting five clinical trials in oncology with two products carrying tumor suppressor genes within the SGT proprietary nanocomplex. The lead products, SGT-53 and SGT-94, are being evaluated as single agents and in combination with standard cancer therapies at leading cancer treatment centers including MD Anderson and Texas Children's Hospital. Additionally, small molecule chemotherapeutics have been successfully delivered with high specificity and efficiency to tumors (including brain tumors) via the SGT nanocomplex.

Cancer Imaging: SGT's versatile nanodelivery system can also carry contrast agents for MRI of tumors as well as fluorescent payloads for intraoperative demarcation of tumor margins.

Non-cancer Applications: In non-tumor-bearing animals, the SGT nanocomplex is capable of delivering its payloads to the deep brain, to liver and to muscle. This capability is the basis of a multi-year grant from the U.S. Department of Defense for countering chemical warfare agents and will ultimately broaden SGT's target markets beyond oncology.